Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Cardio-Oncology: Clinical Advances in Cardiotoxicity Detection, Imaging and Therapeutic Strategies
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Cardio-Oncology: Clinical Advances in Cardiotoxicity Detection, Imaging and Therapeutic Strategies

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (20 February 2026) | Viewed by 3314

Special Issue Editors

Dr. Nicola Maurea

E-Mail Website
Guest Editor
Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy
Interests: Cardiovascular Diseases; Echocardiography; clinical and translational cardioncology; Cardiotoxicity
Dr. Alfredo Mauriello

E-Mail Website
Guest Editor
Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy
Interests: minimally invasive cardiac care; heart failure; heart valve disease; echocardiography; intensive cardiac care; Marfan syndrome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardio-oncology is a rapidly expanding field, crucial for improving the long-term outcomes of cancer patients, given the increasing cancer survival rates and the concomitant incidence of treatment-induced cardiovascular toxicity. This Special Issue aims to provide an update on the latest discoveries, covering the entire spectrum of cardio-oncology. We anticipate receiving manuscripts that explore the pathophysiology, risk factors, and clinical manifestations underlying cardiotoxicity from chemotherapeutic agents and new targeted therapies. We also seek articles focused on the use of advanced imaging techniques (3D echocardiography, cardiac magnetic resonance imaging, PET/CT) for early diagnosis and risk stratification of cardiac dysfunction, as well as contributions concerning innovative therapeutic strategies, including new cardioprotective molecules and personalized approaches for managing cardiovascular complications in cancer patients. Our goal is to provide a comprehensive resource that stimulates further research and improves clinical practice in this vital field.

Dr. Nicola Maurea
Dr. Alfredo Mauriello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardio-oncology
  • cardiovascular toxicity
  • targeted therapies
  • echocardiography
  • PET/CT

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 1265 KB  
Article
Effect of Immune Checkpoint Inhibitor Therapy on Biventricular and Biatrial Mechanics in Patients with Advanced Cancer: A Short-Term Follow-Up Study
by Andrea Sonaglioni, Emanuela Fossile, Nicoletta Tartaglia, Gian Luigi Nicolosi, Michele Lombardo, Massimo Baravelli, Paola Muti and Pier Francesco Ferrucci
J. Clin. Med. 2026, 15(2), 762; https://doi.org/10.3390/jcm15020762 - 16 Jan 2026
Cited by 1 | Viewed by 541
Abstract
Background: Immune checkpoint inhibitors (ICIs) improve cancer outcomes but may cause cardiovascular toxicity, including early subclinical myocardial injury. Conventional echocardiography has limited sensitivity, whereas speckle-tracking echocardiography (STE) allows for early detection of myocardial deformation. Data on short-term ICI-related effects on biventricular mechanics [...] Read more.
Background: Immune checkpoint inhibitors (ICIs) improve cancer outcomes but may cause cardiovascular toxicity, including early subclinical myocardial injury. Conventional echocardiography has limited sensitivity, whereas speckle-tracking echocardiography (STE) allows for early detection of myocardial deformation. Data on short-term ICI-related effects on biventricular mechanics are limited, and atrial function remains poorly characterized. This study evaluated the early impact of ICI therapy on biventricular and biatrial mechanics using STE in patients with advanced cancer. Methods: In this prospective, single-center study, 28 consecutive patients with advanced cancer undergoing ICI therapy were followed for 3 months. Clinical, laboratory, electrocardiographic, and echocardiographic assessments were performed at baseline, 1 month, and 3 months. STE was used to assess left ventricular global longitudinal strain (LV-GLS) and circumferential strain; right ventricular GLS (RV-GLS); and left and right atrial reservoir, conduit, and contractile strain parameters. Subclinical LV dysfunction was defined as a relative LV-GLS reduction >15%. Logistic and Cox regression analyses identified predictors of strain impairment and adverse clinical events. Results: Conventional echocardiographic parameters, including left ventricular ejection fraction, remained stable. In contrast, LV-GLS declined progressively from 20.7 ± 2.1% to 17.6 ± 2.7% at 3 months (p = 0.002), with subclinical LV dysfunction observed in 85.7% of patients. RV-GLS also deteriorated despite preserved TAPSE. Both left and right atrial strain and strain-rate parameters showed an early and marked decline, accompanied by increased left atrial stiffness despite unchanged atrial volumes. Older age and higher neutrophil-to-lymphocyte ratio (NLR) were associated with LV-GLS impairment. Over a mean follow-up of 5.4 ± 3 months, baseline LV-GLS independently predicted adverse clinical events and mortality. Optimal cut-off values were 67 years for age, 4 for NLR, and 19.5% for LV-GLS. Conclusions: Short-term ICI therapy is associated with early, diffuse subclinical myocardial dysfunction involving both ventricles and atria, detectable only by STE. Comprehensive biventricular and biatrial strain assessment may enhance early cardio-oncology surveillance and risk stratification in ICI-treated patients. Full article
(This article belongs to the Special Issue Cardio-Oncology: Clinical Advances in Cardiotoxicity Detection, Imaging and Therapeutic Strategies)
►▼ Show Figures

Figure 1

11 pages, 1959 KB  
Article
Impact of Acute Lymphoblastic Leukemia Treatment on Left Ventricular Function Assessed in 2D and 3D Speckle Tracing Echocardiography—Preliminary Results
by Julia Haponiuk-Skwarlińska, Halszka Kamińska, Katarzyna Albrecht, Paweł Łaguna and Bożena Werner
J. Clin. Med. 2025, 14(24), 8682; https://doi.org/10.3390/jcm14248682 - 8 Dec 2025
Viewed by 621
Abstract
Background/Objectives: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy with promising survival. ALL treatment involves the use of cardiotoxic anthracyclines. The data for children on new methods of echocardiographic detection of early-onset anthracycline-related left ventricle dysfunction is lacking. Methods: [...] Read more.
Background/Objectives: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy with promising survival. ALL treatment involves the use of cardiotoxic anthracyclines. The data for children on new methods of echocardiographic detection of early-onset anthracycline-related left ventricle dysfunction is lacking. Methods: Consecutive children with ALL were prospectively enrolled. The echocardiography was performed after ALL diagnosis and before initiation of anthracyclines (first assessment) and after induction and intensification therapy completion (second assessment). The left ventricle echocardiographic assessment involved conventional two-dimensional (2D) echocardiography, 2D speckle tracing, and three-dimensional (3D) echocardiography with offline analysis for 3D speckle tracing. Results: The preliminary group of 32 children presented with mean time between the first and second assessment of 7.3 ± 1.5 months (min.5.3–max.11.4). All children were treated by the same treatment protocol and received doxorubicin and daunorubicin. The mean cumulative equivalent anthracycline dose was 165.6 ± 54.0 mg/m2. Statistically significant differences between the first and the second echocardiography were observed in LV-GLS-2D −24.6 ± 3.3% vs. −21.0 ± 3.3%; p < 0.001, LVEF-3D 59.7 ± 7.3% vs. 55.1 ± 3.0%; p = 0.010, LV-GLS-3D −23.3 ± 5.3% vs. −20.4 ± 2.8%; p = 0.031 and LV-GCS-3D −26.3 ± 5.9% vs. −21.9 ± 3.2%; p = 0.017. The differences in LVEF-2D and LV-GRS-3D were not statistically significant. The decrease of >15% from the first assessment was observed in 9 (28%) in LV-GLS-2D, 8 (25%) in LV-GLS-3D, 11 (34%) in LV-GCS-3D and only in 4 (13%) patients in LV-GRS-3D. Conclusions: Two-dimensional and three-dimensional speckle tracing and 3D-LVEF may be sensitive indicators of subclinical left ventricular function impairment in children treated for ALL with anthracyclines. However, this is a preliminary analysis of the planned cohort; our results should be interpreted with caution. Full article
(This article belongs to the Special Issue Cardio-Oncology: Clinical Advances in Cardiotoxicity Detection, Imaging and Therapeutic Strategies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 1351 KB  
Review
Factor XI and Cancer: Physiopathological Linkage and Clinical Perspectives
by Alfredo Mauriello, Anna Chiara Maratea, Celeste Fonderico, Vincenzo Quagliariello, Fabrizio Maurea and Nicola Maurea
J. Clin. Med. 2025, 14(17), 6341; https://doi.org/10.3390/jcm14176341 - 8 Sep 2025
Cited by 3 | Viewed by 1695
Abstract
Thrombotic complications are a common cause of morbidity and mortality in cancer patients. Factor XI (FXI) appears to play a direct role not only in thrombotic pathogenesis but also in cancer progression. This comprehensive review aims to define the pathophysiological relationships between FXI [...] Read more.
Thrombotic complications are a common cause of morbidity and mortality in cancer patients. Factor XI (FXI) appears to play a direct role not only in thrombotic pathogenesis but also in cancer progression. This comprehensive review aims to define the pathophysiological relationships between FXI and cancer and to assess existing therapeutic opportunities targeting this factor. This review highlights how FXI is implicated in tumor growth, tumor cell adhesion and migration, inflammation, and angiogenesis. FXI inhibition has been shown to reduce the risk of thrombosis, with a potentially improved safety profile in terms of bleeding risk. Several molecules, such as asundexian and abelacimab, are in clinical trials for the prevention and treatment of venous thromboembolic events, catheter-related thrombosis, and arterial thromboembolic events in cancer patients. In conclusion, factor XI is closely linked to the pathogenesis of cancer and its thromboembolic complications. The use of FXI inhibitors emerges as a promising therapeutic strategy, offering potentially positive effects in the prevention and treatment of thromboembolic complications without significantly increasing the risk of bleeding, a limitation of conventional anticoagulants. The preliminary evidence is that further clinical trials are required and that the available data is not enough to make firm clinical recommendations. Full article
(This article belongs to the Special Issue Cardio-Oncology: Clinical Advances in Cardiotoxicity Detection, Imaging and Therapeutic Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop